Access and Utilization of New Antidepressant and Antipsychotic Medications : Table 1

01/01/2000

: Table 1

CHAPTER I.INTRODUCTION
Exhibit I-1.Representative Antidepressants Marketed in the United States, 1999
Exhibit I-2.Representative Antipsychotics Marketed in the United States, 1999
Exhibit I-3.List of Key Informants
CHAPTER IV.THE CURRENT STATE OF ACCESS TO NEWER ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATIONS
Exhibit IV-1.Reimbursement Mechanisms for Pharmacy Benefit under Medicaid and State Mental Health System Programs
Exhibit IV-2.Relative Importance of Issues Affecting Formulary Decisions
Exhibit IV-3.Formulary Status of Antidepressants in 41 Managed Care Plans
Exhibit IV-4.Formulary Status of Antipsychotics in 41 Managed Care Plans
Exhibit IV-5.Formulary Status of Lipid Lowering Agents (Statins) in 40 Managed Care Plans
CHAPTER VI.PATTERNS OF ANTIPSYCHOTIC AND ANTIDEPRESSANT UTILIZATION IN MEDICAID, 1995-1998
Exhibit VI-1.Antipsychotic Categories
Exhibit VI-2.Market Share of Antipsychotic Classes in 45 Medicaid States, 1998.
Exhibit VI-3.Market Share of Antipsychotic Classes in 45 Medicaid States, 1998.
Exhibit VI-4.Share of Medicaid Antipsychotic Prescriptions and Expenditures by Class, 1998
Exhibit VI-5.Antipsychotic Prescription Trends in Medicaid, 1995-1998
Exhibit VI-6.Antipsychotic Prescription Trends in Medicaid, Total Expenditures, 1995-1998
Exhibit VI-7.Antipsychotic Prescription Trends in Medicaid by Class, 1995-1998
Exhibit VI-8.Antipsychotic Prescription Trends in Medicaid, Total Expenditures by Class, 1995-1998
Exhibit VI-9.Number of Antipsychotic Prescriptions and Total Amount of Medicaid Reimbursement 12 High-Volume Prescription States, 1998
Exhibit VI-10.Market Share of Antipsychotics in 12 High-Volume Medicaid States as a Percent of Total Antipsychotic Prescriptions, 1998
Exhibit VI-11.Uptake of Newer Antipsychotic Medications in Medicaid and Growth of Prescription Volume 1996-1998
Exhibit VI-12.Antidepressant Classes
Exhibit VI-13.Market Share of Antidepressant Classes in 45 Medicaid States, 1998.
Exhibit VI-14.Market Share of Antidepressant Classes in 45 State Medicaid Programs, 1998.
Exhibit VI-15.Share of Medicaid Antidepressant Prescriptions and Expenditures by Class, 1998
Exhibit VI-16.Antidepressant Prescription Trends in Medicaid, 1995-1998. Total Prescriptions in Thousands
Exhibit VI-17.Antidepressant Prescription Trends in Medicaid, 1995-1998. Expenditures in Millions
Exhibit VI-18.Antidepressant Class Prescription Trends in Medicaid, 1995-1998. Total Prescriptions inThousands
Exhibit VI-19.Antidepressant Class Prescription Trends in Medicaid, 1995-1998. Total Expenditures in Millions
Exhibit VI-20.Number of Antidepressant Prescriptions and Total Amount of Medicaid Reimbursement for 12 High Volume States, 1995-1998
Exhibit VI-21.Market Share of Antidepressants in 12 High-Volume Medicaid States as Percent of Total Prescriptions, 1998
Exhibit VI-22.Oral Antidiabetic Categories
Exhibit VI-23.Comparison of Increase in Prescriptions and Expenditures for 3 Pharmaceutical Classes in Medicaid, 1995-1998
CHAPTER VII.PHARMACOECONOMICS OF NEWER ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATIONS
Exhibit VII-1.Comparison of Pharmacoeconomic Methodologies
Exhibit VII-2.Studies Using Hospitalization as a Proxy for Costs in Treatment with Risperidone or Clozapine
Exhibit VII-3.Historical Comparison Studies with Clozapine